

ELECTRONIC INFORMATION DISCLOSURE STATEMENT

Electronic Version v18

Stylesheet Version v18.0

Title of Invention

Cobalamin conjugates for anti-tumor therapy

Application Number : 10/659501

Confirmation Number: 7515

First Named Applicant: Ned Weinshenker

Attorney Docket Number: MCP-1

Art Unit: 1614

Examiner:

Search string: (5863900 or 6262253 or 5807832 or 5739287 or 5589463 or 6315978 or 5428023 or 6083926 or 3130189 or 5449720 or 5548064 or 5869466 or 6150341).pn



US Patent Documents

Note: Applicant is not required to submit a paper copy of cited US Patent Documents

init	Cite.No.	Patent No.	Date	Patentee	Kind	Class	Subclass
	1	5863900	1999-01-26	Russell-Jones	A1	514	15
	2	6262253	2001-07-17	Russell-Jones	A1	536	26.41
	3	5807832	1998-09-15	Russell-Jones	A1	514	21
	4	5739287	1998-04-14	Wilbur	A1	530	367
	5	5589463	1996-12-31	Russell-Jones	A1	514	21
	6	6315978	2001-11-13	Grissom	A1	424	1.53
	7	5428023	1995-06-27	Russell-Jones	A1	514	21
	8	6083926	2000-07-04	Morgan Jr.	A1	514	52
	9	3130189	1964-04-21	Hannus	A1	260	112
	10	5449720	1995-09-12	Russell-Jones	A1	525	54.1
	11	5548064	1996-04-20	Russell-Jones	A1	530	380
	12	5869466	1999-02-09	Russell-Jones	A1	514	52
	13	6150341	2000-11-21	Russell-Jones	A1	514	52

Remarks

Note: Remarks are not for responding to an office action.

Applicants hereby submit the present INFORMATION DISCLOSURE STATEMENT. Applicants submit herewith patents, publications or other information which may be material to the examination of this application and for which there may be a duty to disclose in accordance with 37 CFR 1.56. The filing of this Information Disclosure Statement shall not be construed as a representation that a search has been made (37 CFR 1.56(g)), or as an admission that the

information cited is, or is considered to be, material to patentability. The filing of this Information Disclosure Statement shall not be construed as an admission against interest in any manner. It is respectfully requested that the references identified in this Information Disclosure Statement be considered by the Examiner, be made a part of the official record, and be cited in the issued patent. The person making this statement is the agent on the basis of information in the agent's file.

Signature

Examiner Name	Date